Latest Contracts News

NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.

Gold Hydrogen is poised to begin flow testing at its Ramsay Project, targeting separate Natural Hydrogen and Helium zones, while advancing green methanol and helium commercialisation studies amid robust market demand.

dorsaVi has launched a multi-year partnership with Taiwan’s ITRI and NTU to develop its proprietary RRAM platform at the 22-nm node, complemented by a new advisory board and neuromorphic IP acquisition, positioning the company at the forefront of ultra-edge AI hardware.

Stockland reports strong leasing growth and development momentum in 3Q26, highlighting new data centre and land lease partnerships while maintaining FY26 guidance.

Ausgold has locked in a $30.1 million EPC contract with ADD Business Group to build a 250-room workforce village near its Katanning Gold Project, marking a key step towards a final investment decision in late 2026.

Dateline Resources is poised to release its Colosseum Gold Project Bankable Feasibility Study imminently, while expanding rare earth exploration at its new Music Valley project and bolstering its balance sheet with a $50 million placement.

Beetaloo Energy has bolstered its financial footing with a $66.3 million equity placement and a $15.4 million R&D tax refund, underpinning key developments at the Carpentaria Gas Plant and local frac sand project.

Livium Ltd boosted battery recycling revenue and secured a new centralised hub to expand capacity, while advancing rare earth and solar panel recycling technologies. Strategic funding for its lithium cathode plant remains under review.

Australian Strategic Materials reports a 70% surge in NdFeB alloy production, installs pilot heavy rare earth furnace, and progresses its acquisition by Energy Fuels with regulatory approvals underway.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.

ImpediMed reported a $3.5 million revenue in Q3 FY26, with reimbursement coverage in the US reaching 94.3%, supporting growth in heart health and weight management markets. New CEO Erik Anderson aims to accelerate commercial momentum and drive cash flow break-even.